Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Kymera Therapeutics Inc
(NQ:
KYMR
)
33.97
-1.15 (-3.27%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
627,447
Open
34.98
Bid (Size)
33.97 (2)
Ask (Size)
36.68 (1)
Prev. Close
35.12
Today's Range
33.35 - 35.53
52wk Range
9.600 - 45.31
Shares Outstanding
55,307,775
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual Meeting
April 08, 2024
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Kymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs at the American Academy of Dermatology Annual Meeting
March 08, 2024
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Performance
YTD
+34.00%
+34.00%
1 Month
-15.77%
-15.77%
3 Month
+23.57%
+23.57%
6 Month
+179.59%
+179.59%
1 Year
+0.32%
+0.32%
More News
Read More
Kymera Therapeutics to Participate in Upcoming March Investor Conferences
February 28, 2024
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Breaking Down Kymera Therapeutics: 4 Analysts Share Their Views
February 23, 2024
Via
Benzinga
Deep Dive Into Kymera Therapeutics Stock: Analyst Perspectives (4 Ratings)
December 19, 2023
Via
Benzinga
Analyst Expectations for Kymera Therapeutics's Future
November 13, 2023
Via
Benzinga
Piper Sandler Maintains Overweight Rating for Kymera Therapeutics: Here's What You Need To Know
February 27, 2024
Via
Benzinga
Kymera Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update
February 22, 2024
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Kymera Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 22
February 15, 2024
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Kymera Therapeutics to Present in Fireside Chat at the Guggenheim Healthcare Conference
January 31, 2024
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Earnings Scheduled For February 22, 2024
February 22, 2024
Via
Benzinga
Kymera Therapeutics Outlines Key 2024 Objectives and Strategy to Progress Leading Portfolio of Immunology and Oncology Programs
January 09, 2024
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Kymera Therapeutics Announces Closing of Upsized $275 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
January 09, 2024
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Kymera Therapeutics Stock Whiplash: Shares Soar, Then Tumble After $275 Million Offering
January 05, 2024
Via
Investor's Business Daily
Kymera Therapeutics Announces Pricing of $275 Million Public Offering
January 05, 2024
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Kymera Therapeutics Announces Proposed Public Offering
January 04, 2024
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
R&D Day Highlights Kymera’s Immunology Strategy and Emerging Pipeline of Novel, First-in-Class Oral Degraders Addressing Multiple Highly Prevalent Immuno-inflammatory Diseases
January 04, 2024
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Kymera Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024
January 02, 2024
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Kymera Therapeutics to Host Virtual Immunology R&D Day on January 4
December 13, 2023
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Kymera Therapeutics Presents Interim Results from STAT3 Degrader Phase 1 Clinical Trial at American Society of Hematology Annual Meeting
December 10, 2023
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Kymera Therapeutics Announces First Patient Dosed in Phase 2 Atopic Dermatitis Clinical Trial of KT-474 (SAR444656), a First-in-Class, Investigational IRAK4 Degrader, Generating a $15 Million Payment from Sanofi
December 07, 2023
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Kymera Therapeutics Announces Publication of Phase 1 Trial Results for KT-474 (SAR444656), a First-in-Class IRAK4 Degrader, in Nature Medicine
November 13, 2023
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
More Than $10M Bet On This Healthcare Stock? Check Out These 4 Stocks Insiders Are Buying
November 07, 2023
Via
Benzinga
HC Wainwright & Co. Maintains Buy Rating for Kymera Therapeutics: Here's What You Need To Know
November 03, 2023
Via
Benzinga
Kymera Therapeutics to Present New Clinical Data from the Phase 1 Trial of STAT3 Degrader KT-333 at the ASH Annual Meeting
November 02, 2023
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.